Infliximab (anti-TNF-alpha)

Catalog No.A2019 Synonyms: Remicade, Remsima, Inflectra

For research use only.
Not for use in humans.

Infliximab (anti-TNF-alpha) (Remicade, Remsima, Inflectra) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.

Quality Control

Choose Selective TNF-alpha Inhibitors

Biological Activity

Description Infliximab (anti-TNF-alpha) (Remicade, Remsima, Inflectra) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.
In vitro

Infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition.[1] Infliximab does not exacerbate production of inflammatory cytokines, and does not affect expression of TNFR, proliferation of ARPE-19, HTLV-1 proviral load, or apoptosis of ARPE-19. Infliximab does not exacerbate HTLV-1-related inflammation in the eye and represents an acceptable treatment option under HTLV-1 infectious conditions.[3]

In vivo

A single injection of infliximab in diabetic TNF-α(+/+) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 wk. Moreover, the increased TNF-α mRNA expression in diabetic DRG is also attenuated by infliximab, suggesting infliximab's effects may involve the local suppression of TNF-α. Infliximab, an agent currently in clinical use, is effective in targeting TNF-α action and expression and amelioration of diabetic neuropathy in mice.[2] Mice given increasing doses of infliximab produces increasing levels of ADAs. Blood samples from mice given injections of human TNF and infliximab contains infliximab-TNF complexes.[4]

Protocol

Cell Research:
- Collapse
  • Objective: Glucose uptake assay
    Cells: murine 3T3L1 cell line
    Concentrations: 10 ng/ml
    Incubation Time: 2 hr
    Method: For glucose uptake assay, 3T3L1 mature adipocytes are in vitro cultured for 2 hr at 37°C in humidified 5% CO2 atmosphere, using 6-well cell-culture plates at a density of 30×104 cells per well. Adipocytes are stimulated twice at zero and 60 minutes with 2 μM insulin. In the infliximab-treated group, adipocytes are stimulated with 10 ng/ml infliximab at the beginning of the 2-hr in vitro assay.
    Reference: https://pubmed.ncbi.nlm.nih.gov/30260514

    Objective: Cell Counts
    Cells: ARPE-19 cells, MT-2 cells, Jurkat cells
    Concentrations: 10 μg/ml
    Incubation Time: 24 h, 48 h, 72 h
    Method: ARPE-19 cells (2 × 104) are co-cultured with three times the number of MT2 or Jurkat cells with or without Infliximab. After 0, 24, 48, or 72 h of co-culture, we remove the supernatants, trypsinized ARPE-19, and count the number of ARPE-19 cells under light microscopy.
    Reference: https://pubmed.ncbi.nlm.nih.gov/31620105

    Infliximab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Animal Research:
- Collapse
  • Objective: To evaluate the effect on diabetic neuropathy
    Animal Models: 8-week-old C57BL/6J (WT, TNF-α+/+) and TNF-α-deficient (TNFα−/−) mice of strain B6.129S6-Tnftm1Gkl/J in the C57BL/6 background
    Formulation: Saline
    Dosages: 10 μg/g
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/21810933

    Objective: pharmacokinetic (PK) study
    Animal Models: 6–8 week-old female C57BL/6 mice
    Formulation: --
    Dosages: 0.3075 μg/g, 0.384 μg/g, 0.769 μg/g, 1.538 μg/g, 6.15 μg/g, 30.75 μg/g, 246 μg/g
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/31401142

    Infliximab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Product Details

CAS No. 170277-31-3
Isotype Chimeric IgG1
Source Chimeric (mouse/human)
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

TNF-alpha Signaling Pathway Map

Related TNF-alpha Products

Tags: buy Infliximab (anti-TNF-alpha) | Infliximab (anti-TNF-alpha) supplier | purchase Infliximab (anti-TNF-alpha) | Infliximab (anti-TNF-alpha) cost | Infliximab (anti-TNF-alpha) manufacturer | order Infliximab (anti-TNF-alpha) | Infliximab (anti-TNF-alpha) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID